Sequential Use of Ad26-based Vaccine Regimens in NHP to Induce Immunity Against Different Disease Targets

Overview

Journal NPJ Vaccines

Date 2022 Nov 15

PMID 36379957

Authors

Selina Khan

Nadine C Salisch

Ana Izquierdo Gil

Satish Boedhoe

Karin Feddes-de Boer

Jan Serroyen

Hanneke Schuitemaker

Roland C Zahn

Affiliations

Soon will be listed here.

Abstract

The adenovirus (Ad)26 serotype-based vector vaccine Ad26.COV2.S has been used in millions of subjects for the prevention of COVID-19, but potentially elicits persistent anti-vector immunity. We investigated if vaccine-elicited immunity to Ad26 vector-based vaccines significantly influences antigen-specific immune responses induced by a subsequent vaccination with Ad26 vector-based vaccine regimens against different disease targets in non-human primates. A homologous Ad26 vector-based vaccination regimen or heterologous regimens (Ad26/Ad35 or Ad26/Modified Vaccinia Ankara [MVA]) induced target pathogen-specific immunity in animals, but also persistent neutralizing antibodies and T-cell responses against the vectors. However, subsequent vaccination (interval, 26-57 weeks) with homologous and heterologous Ad26 vector-based vaccine regimens encoding different target pathogen immunogens did not reveal consistent differences in humoral or cellular immune responses against the target pathogen, as compared to responses in naïve animals. These results support the sequential use of Ad26 vector-based vaccine regimens targeting different diseases.

Citing Articles

Safety and immunogenicity of Ad26.COV2.S in adolescents: Phase 2 randomized clinical trial.

Tica J, Rezelj V, Baron B, van Paassen V, Zaidman J, Fairlie L Hum Vaccin Immunother. 2025; 21(1):2450120.

PMID: 39868766 PMC: 11776467. DOI: 10.1080/21645515.2025.2450120.

A replication-incompetent adenoviral vector encoding for HSV-2 gD2 is immunogenic and protective against HSV-2 intravaginal challenge in mice.

Rossetti E, Vujadinovic M, van Huizen E, Tolboom J, Schuitemaker H, Yao F PLoS One. 2024; 19(12):e0310250.

PMID: 39739963 PMC: 11687876. DOI: 10.1371/journal.pone.0310250.

Adenoviral Vector System: A Comprehensive Overview of Constructions, Therapeutic Applications and Host Responses.

Park A, Lee J J Microbiol. 2024; 62(7):491-509.

PMID: 39037484 DOI: 10.1007/s12275-024-00159-4.

Effect of Prior ChAdOx1 COVID-19 Immunisation on T-Cell Responses to ChAdOx1-HBV.

Davis C, Singh D, Anderson K, Vardeu A, Kopycinski J, Bridges-Webb A Vaccines (Basel). 2024; 12(6).

PMID: 38932373 PMC: 11209196. DOI: 10.3390/vaccines12060644.

Peak transgene expression after intramuscular immunization of mice with adenovirus 26-based vector vaccines correlates with transgene-specific adaptive immune responses.

Marquez-Martinez S, Salisch N, Serroyen J, Zahn R, Khan S PLoS One. 2024; 19(4):e0299215.

PMID: 38626093 PMC: 11020485. DOI: 10.1371/journal.pone.0299215.

References

Abbink P, Lemckert A, Ewald B, Lynch D, Denholtz M, Smits S . Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol. 2007; 81(9):4654-63. PMC: 1900173. DOI: 10.1128/JVI.02696-06. View

Zahn R, Gillisen G, Roos A, Koning M, van der Helm E, Spek D . Ad35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus species. PLoS One. 2012; 7(12):e44115. PMC: 3516506. DOI: 10.1371/journal.pone.0044115. View

Quinn K, Zak D, Costa A, Yamamoto A, Kastenmuller K, Hill B . Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling. J Clin Invest. 2015; 125(3):1129-46. PMC: 4362254. DOI: 10.1172/JCI78280. View

Tiono A, Nebie I, Anagnostou N, Coulibaly A, Bowyer G, Lam E . First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children. PLoS One. 2018; 13(12):e0208328. PMC: 6291132. DOI: 10.1371/journal.pone.0208328. View

Fausther-Bovendo H, Kobinger G . Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what's important?. Hum Vaccin Immunother. 2014; 10(10):2875-84. PMC: 5443060. DOI: 10.4161/hv.29594. View

Slike B, Creegan M, Marovich M, Ngauy V . Humoral Immunity to Primary Smallpox Vaccination: Impact of Childhood versus Adult Immunization on Vaccinia Vector Vaccine Development in Military Populations. PLoS One. 2017; 12(1):e0169247. PMC: 5207489. DOI: 10.1371/journal.pone.0169247. View

Catanzaro A, Koup R, Roederer M, Bailer R, Enama M, Moodie Z . Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis. 2006; 194(12):1638-49. PMC: 2428071. DOI: 10.1086/509258. View

Barouch D, Tomaka F, Wegmann F, Stieh D, Alter G, Robb M . Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet. 2018; 392(10143):232-243. PMC: 6192527. DOI: 10.1016/S0140-6736(18)31364-3. View

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

10.

Sprangers M, Lakhai W, Koudstaal W, Verhoeven M, Koel B, Vogels R . Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol. 2003; 41(11):5046-52. PMC: 262545. DOI: 10.1128/JCM.41.11.5046-5052.2003. View

11.

Baden L, Walsh S, Seaman M, Cohen Y, Johnson J, Licona J . First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector. J Infect Dis. 2018; 218(4):633-644. PMC: 6047429. DOI: 10.1093/infdis/jiy212. View

12.

Li J, Hou L, Meng F, Wu S, Hu Y, Liang Q . Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Glob Health. 2016; 5(3):e324-e334. DOI: 10.1016/S2214-109X(16)30367-9. View

13.

Folegatti P, Ewer K, Aley P, Angus B, Becker S, Belij-Rammerstorfer S . Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396(10249):467-478. PMC: 7445431. DOI: 10.1016/S0140-6736(20)31604-4. View

14.

Baden L, Stieh D, Sarnecki M, Walsh S, Tomaras G, Kublin J . Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study. Lancet HIV. 2020; 7(10):e688-e698. PMC: 7529856. DOI: 10.1016/S2352-3018(20)30229-0. View

15.

Williams K, Bastian A, Feldman R, Omoruyi E, De Paepe E, Hendriks J . Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years. J Infect Dis. 2020; 222(6):979-988. DOI: 10.1093/infdis/jiaa193. View

16.

Cooney E, Collier A, Greenberg P, Coombs R, Zarling J, Arditti D . Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet. 1991; 337(8741):567-72. DOI: 10.1016/0140-6736(91)91636-9. View

17.

McElrath M, De Rosa S, Moodie Z, Dubey S, Kierstead L, Janes H . HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet. 2008; 372(9653):1894-1905. PMC: 2774110. DOI: 10.1016/S0140-6736(08)61592-5. View

18.

Priddy F, Brown D, Kublin J, Monahan K, Wright D, Lalezari J . Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis. 2008; 46(11):1769-81. DOI: 10.1086/587993. View

19.

Maizel Jr J, WHITE D, Scharff M . The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology. 1968; 36(1):115-25. DOI: 10.1016/0042-6822(68)90121-9. View

20.

McCoy K, Tatsis N, Korioth-Schmitz B, Lasaro M, Hensley S, Lin S . Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. J Virol. 2007; 81(12):6594-604. PMC: 1900096. DOI: 10.1128/JVI.02497-06. View